Bioprojet

Bioprojet company information, Employees & Contact Information

Explore related pages

Related company profiles:

Bioprojet is a pharmaceutical laboratory committed to science and health. In the last 40 years, we’ve brought forward breakthrough medicines, helping patients struggling with challenging diseases. With passion and integrity, we follow the path set by Jeanne-Marie Lecomte and Jean-Charles Schwartz, founders of Bioprojet. At Bioprojet, we grow to keep honoring our motto : Passion for Research. Research for Patients. Read our terms of use ➡️ https://bit.ly/3pYjQOp

Company Details

Employees
157
Address
9 Rue Rameau, Paris,75002,france
Phone
+33 (0)1 47 03 66 33
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Paris
Looking for a particular Bioprojet employee's phone or email?

Bioprojet Questions

News

Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia - BioSpace

Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia BioSpace

HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST - PR Newswire

HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST PR Newswire

Montco pharma makes licensing deal valued at up to $393M - The Business Journals

Montco pharma makes licensing deal valued at up to $393M The Business Journals

Harmony Biosciences (HRMY) Enters into a License Agreement with Bioprojet - StreetInsider

Harmony Biosciences (HRMY) Enters into a License Agreement with Bioprojet StreetInsider

Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysis - The Lancet

Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysis The Lancet

Bioprojet: WAKIX® (pitolisant) receives approval for the treatment of narcolepsy in children over 6 years of age, a rare, under-diagnosed condition - PR Newswire UK

Bioprojet: WAKIX® (pitolisant) receives approval for the treatment of narcolepsy in children over 6 years of age, a rare, under-diagnosed condition PR Newswire UK

After Twist and Ginkgo campaigns, Scorpion Capital aims stinger at Harmony Biosciences - Fierce Pharma

After Twist and Ginkgo campaigns, Scorpion Capital aims stinger at Harmony Biosciences Fierce Pharma

China’s NMPA approves RareStone's Wakix for narcolepsy - The Pharma Letter

China’s NMPA approves RareStone's Wakix for narcolepsy The Pharma Letter

BPS Publications - British Pharmacological Society | Journals

BPS Publications British Pharmacological Society | Journals

Bioprojet: European Marketing Authorisation for OZAWADE™ - PR Newswire

Bioprojet: European Marketing Authorisation for OZAWADE™ PR Newswire

Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts - BioSpace

Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts BioSpace

Harmony Biosciences scores first approval in narcolepsy med Wakix - Fierce Pharma

Harmony Biosciences scores first approval in narcolepsy med Wakix Fierce Pharma

HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY - PR Newswire

HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY PR Newswire

Harmony Biosciences Acquires US Rights to Pitolisant From Bioprojet; Raises $270 Million in Equity Financing - PR Newswire

Harmony Biosciences Acquires US Rights to Pitolisant From Bioprojet; Raises $270 Million in Equity Financing PR Newswire

HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1 - PR Newswire

HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1 PR Newswire

Harmony Biosciences Acquires Asset With Novel Mechanism Of Action For The Potential Treatment Of Narcolepsy And Other Rare Neurological Diseases - PR Newswire

Harmony Biosciences Acquires Asset With Novel Mechanism Of Action For The Potential Treatment Of Narcolepsy And Other Rare Neurological Diseases PR Newswire

Bioprojet: Pitolisant Progresses Towards the U.S. Market - PR Newswire UK

Bioprojet: Pitolisant Progresses Towards the U.S. Market PR Newswire UK

Top Bioprojet Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant